Skip to main content

clindamycin

Generic: CLINDAMYCIN PHOSPHATE·Brand: ANTIROBE, Acanya, CLEOCIN, CLEOCIN HYDROCHLORIDE, CLEOCIN PHOSPHATE, CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLEOCIN T, CLINDA-DERM, CLINDAGEL, CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDESSE, CLINDETS, Cabtreo, Cleocin, Cleocin-T, Clinda-Guard, ClindaCure, Clindacin, Clindagel, Clindamax, Clindesse, Clintabs, EVOCLIN, Evoclin, Neuac, Onexton, Veltin, XACIATO, Xaciato, Ziana, Zydaclin

clindamycin: 3 clinical trials tracked.

clindamycin evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about clindamycin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Acne Vulgaris

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

Satisfaction, Adherence, Effectiveness, and Safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Treatment in Patients With Acne Vulgaris: A Canadian Prospective Phase IV Study (CHARM)

NCT07205107Registry updated 2026-04-01
Active, not recruiting

Primary endpoint: Treatment Satisfaction at Week-12 as assessed by DermSat-7

Observational200 targetStarted 2025-10Completion 2026-0819 sites · CanadaBausch Health Americas, Inc.

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

NCT06120140Registry updated 2026-09-25·Phase 2
Active, not recruiting

Primary endpoint: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment

InterventionalRandomizedopen305 enrolledStarted 2024-02Completion 2030-0650 sites · Argentina, Brazil, China, United StatesJanssen Research & Development, LLC

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118Registry updated 2026-02-11·N/A
Recruiting

Primary endpoint: M/P ratio

Observational1,600 targetStarted 2018-10Completion 2027-0722 sites · Canada, United StatesDuke University